Skip to main content
    I

    InMode Ltd (INMD)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $14.32
    +0.04 (+0.28%)

    Market Cap: $821.73M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    66%(19/29)
    Avg Surprise
    +3.40%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.32
    Range$0.28 - $0.34
    5 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$0.34-5.4%
    60d ago$0.34-4.7%
    30d ago$0.34-4.7%
    7d ago$0.31+2.8%
    Current$0.32
    Revenue Consensus
    $92M
    Range$88M - $93M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.34
    Range$0.28 - $0.39
    5 analysts
    Revenue Consensus
    $105M
    Range$104M - $107M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.34---
    Sep 26EST
    		-$0.32---
    Jun 26
    Reported Jul 24
    		$0.29$0.33-12.12%Miss-38.3%
    Mar 26
    Reported May 6
    		$0.25$0.30-16.67%Miss-19.4%
    Dec 25
    Reported Feb 10
    		$0.46$0.42+9.52%Beat+9.5%
    Sep 25
    Reported Nov 5
    		$0.34$0.35-2.86%Miss-51.4%
    Jun 25
    Reported Jul 30
    		$0.47$0.41+14.63%Beat+38.2%
    Mar 25
    Reported Apr 28
    		$0.31$0.35-11.43%Miss-3.1%
    Dec 24
    Reported Feb 4
    		$0.42$0.50-16.00%Miss-40.8%
    Sep 24
    Reported Oct 30
    		$0.70$0.61+14.75%Beat+14.8%
    Jun 24
    Reported Aug 1
    		$0.34$0.38-10.53%Miss-52.8%
    Mar 24
    Reported May 2
    		$0.32$0.41-21.95%Miss-38.5%
    Dec 23
    Reported Feb 13
    		$0.71$0.67+5.97%Beat-9.0%
    Sep 23
    Reported Nov 2
    		$0.61$0.63-3.17%Miss-7.6%
    Jun 23
    Reported Jul 27
    		$0.72$0.66+9.09%Beat+22.0%
    Mar 23
    Reported May 2
    		$0.52$0.48+8.33%Beat+30.0%
    Dec 22
    Reported Feb 14
    		$0.78$0.69+13.04%Beat+21.9%
    Sep 22
    Reported Oct 27
    		$0.66$0.59+11.86%Beat+20.0%
    Jun 22
    Reported Jul 28
    		$0.59$0.51+15.69%Beat+15.7%
    Mar 22
    Reported May 2
    		$0.40$0.38+5.26%Beat+14.3%
    Dec 21
    Reported Feb 10
    		$0.64$0.57+12.28%Beat+36.2%
    Sep 21
    Reported Oct 26
    		$0.55$0.50+10.00%Beat+71.9%
    Jun 21
    Reported Jul 28
    		$0.51$0.43+18.60%Beat+325.0%
    Mar 21
    Reported May 5
    		$0.35$0.29+20.69%Beat+133.3%
    Dec 20
    Reported Feb 10
    		$0.47$0.38+23.68%Beat+104.3%
    Sep 20
    Reported Nov 12
    		$0.32$0.24+33.33%Beat+52.4%
    Jun 20
    Reported Aug 5
    		$0.12$0.10+20.00%Beat+1300.0%
    Mar 20
    Reported May 6
    		$0.15$0.16-6.25%Miss-46.4%
    Dec 19
    Reported Feb 18
    		$0.23$0.20+15.00%Beat-4.2%
    Sep 19
    Reported Nov 5
    		$0.21$0.15+40.00%Beat-
    Jun 19
    Reported Aug 8
    		$-0.01N/A-102.22%Miss-
    Mar 19
    Reported May 29
    		$0.28$0.00N/ABeat-
    Sep 18
    Reported Oct 11
    		$0.24$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio10.69EV/EBITDA5.45x
    Price/FCF9.72xFCF Yield10.29%
    Profitability
    Profit Margin20.70%Operating Margin12.80%
    ROE12.30%ROIC11.23%
    Financial Health
    Debt/Equity0.01xInterest CoverageN/A
    Current Ratio8.18xQuick Ratio7.28x
    Trading Statistics
    Beta2.03Avg Volume463.52K
    52-Week High$16.6752-Week Low$12.72

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$14.17
    SMA 20$14.21
    SMA 50$14.67
    SMA 200$14.38
    EMA 10$14.23
    EMA 20$14.30
    EMA 50$14.50
    EMA 200$14.50

    MACD

    Line: -0.11Signal: -0.16Hist: 0.05

    ADX

    ADX: 30.8+DI: 27.2-DI: 25.2

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down80.0
    PSAR$13.96

    Bollinger Bands

    Upper Band$14.49
    Lower Band$13.94
    %B Position383%(Upper)
    Band Width0.69

    RSI (14-Day)

    Neutral
    47.8

    Momentum Oscillators

    Stoch %K68.9
    Stoch %D67.8
    Williams %R-28.2
    ROC (10d)1.9%
    Momentum0.27
    CCI (20d)84.0
    MFI (14d)53.1

    Volatility Measures

    ATR (14d)$0.18(1.3%)
    StdDev (20d)0.14
    Hist Vol11.6%(Low)

    Volume Flow

    VWAP$14.36
    OBV6.6M
    AD Line-14.6M
    CMF (20d)-0.025

    Volume Metrics

    Avg Vol (20d)441.3K
    Vol Ratio1.4x
    VWMA (20d)$14.21

    Pivot Points

    R3$14.41
    R2$14.35
    R1$14.32
    Pivot Point$14.26
    S1$14.22
    S2$14.16
    S3$14.13

    Advanced Oscillators

    TSI-20.56
    Ultimate Osc58.2
    KST-40.29

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$95.59M$82.02M$103.85M$93.17M$95.60M$77.87M$97.85M$130.23M$86.45M$80.28M$126.78M$123.11M
    Cost of Revenue$24.07M$20.46M$22.55M$20.86M$19.15M$16.96M$20.22M$24.05M$17.12M$16.36M$20.26M$20.14M
    Gross Profit$71.52M$61.55M$81.30M$72.31M$76.45M$60.91M$77.64M$106.18M$69.33M$63.92M$106.52M$102.98M
    Operating Expenses$59.26M$51.50M$55.31M$51.41M$53.57M$45.29M$49.77M$57.92M$51.02M$45.83M$55.27M$56.57M
    R&D$3.66M$3.54M$3.51M$3.54M$3.37M$2.90M$2.67M$3.25M$3.70M$3.52M$3.47M$3.27M
    SG&A$4.79M$5.02M$3.39M$2.90M$2.72M$2.67M$2.45M$2.80M$2.27M$2.51M$2.35M$2.48M
    Operating Income$12.26M$10.06M$25.99M$20.90M$22.88M$15.62M$27.86M$48.26M$18.31M$18.09M$51.24M$46.41M
    Interest Income$0$4.30M$0$0$0$6.86M$0$0$0$7.98M$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$19.69M$14.35M$31.29M$25.62M$30.94M$22.48M$32.21M$58.18M$27.00M$26.08M$60.16M$51.36M
    Income Tax Expense$2.63M$2.79M$4.27M$3.75M$4.20M$4.28M$-50,561,000$7.19M$3.19M$2.38M$5.00M$4.84M
    Net Income$17.06M$11.56M$27.02M$21.86M$26.74M$18.20M$82.77M$50.99M$23.82M$23.70M$55.16M$46.52M
    EBITDA$12.44M$14.53M$31.47M$25.77M$31.13M$22.65M$32.46M$48.40M$27.18M$26.24M$60.29M$51.49M
    EBIT$12.26M$14.35M$31.29M$25.62M$30.94M$22.48M$32.21M$48.26M$27.00M$26.08M$60.16M$51.36M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about INMD

    News

    Canaccord keeps Hold rating for InMode stock with USD 15 target

    Canaccord Genuity has reiterated a Hold rating for InMode (INMD) stock, setting a price target of USD 15.00. InMode projects Q3 2026 revenue to be between USD 91.8 million and USD 92.0 million...

    ad-hoc-news.de•10/15/26•Neutral

    InMode to Report Third Quarter 2026 Financial Results on November 11, 2026, Expects Third Quarter Revenue of $91.8 Million to $92.0 Million, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

    InMode Ltd. announced preliminary financial results for the third quarter of 2026, expecting revenue between $91.8 million and $92.0 million. The company also reiterated its full-year 2026 revenue guidance of $365...

    PR Newswire•10/13/26•Somewhat-Bullish

    InMode to Report Third Quarter 2026 Financial Results on November 11, 2026, Expects Third Quarter Revenue of $91.8 Million to $92.0 Million, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

    InMode Ltd. announced preliminary financial results for the third quarter of 2026, expecting revenue between $91.8 million and $92.0 million. The company also reiterated its full-year 2026 revenue guidance of $365...

    PR Newswire•10/13/26•Somewhat-Bullish

    InMode launches Morpheus8 Cool: InMode stock sits below USD 16 target

    InMode launched Morpheus8 Cool in September 2026, an addition to its medical aesthetic systems portfolio, coinciding with its stock trading below the average analyst target of USD 16.00. The company reported strong...

    ad-hoc-news.de•10/12/26•Neutral

    Liquidity Mapping Around (INMD) Price Events

    This article analyzes Inmode Ltd. (NASDAQ: INMD) focusing on liquidity mapping and price events, highlighting a neutral sentiment across all time horizons. It details institutional trading strategies, including position...

    Stock Traders Daily•10/12/26•Neutral

    INMD Valuation and Fair Value

    P/E
    10.7x
    Forward P/E
    10.0x
    EV/EBITDA
    5.4x
    P/FCF
    9.7x
    PEG
    2.9x
    P/B
    1.4x
    See GNG's fair value

    INMD Profitability: Margins, ROIC and FCF

    Gross margin
    76.5%
    Operating margin
    12.8%
    Net margin
    20.7%
    ROIC
    11.2%
    ROE
    12.3%
    FCF margin
    23.3%
    FCF yield
    10.3%

    INMD Competitors

    CompanyTicker
    Monte Rosa Therapeutics IncGLUE
    P3 Health Partners IncPIII
    Cullinan Oncology LLCCGEM
    Ardelyx IncARDX
    Alto Neuroscience, Inc.ANRO
    Esperion Therapeutics IncESPR
    Jade Biosciences, Inc.JBIO
    Ginkgo Bioworks HoldingsDNA

    Sector: Healthcare

    INMD Analyst Ratings

    Consensus
    Hold
    Analysts
    5
    Strong Buy
    0
    Buy
    0
    Hold
    5
    Sell
    0
    Strong Sell
    0

    INMD Bull Case vs Bear Case

    Bull case

    • INMD converts 23.3% of revenue into free cash flow.
    • INMD has a 20.7% net profit margin.

    Bear case

    • INMD beat EPS estimates in 37.5% of its last 8 reported quarters.

    INMD Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -2.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.32
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 3 down

    Frequently Asked Questions About INMD

    Does INMD pay dividends?

    InMode Ltd (INMD) does not currently pay a regular dividend.

    What is INMD's P/E ratio?

    InMode Ltd has a price-to-earnings (P/E) ratio of 10.69.

    What is INMD's market cap?

    InMode Ltd (INMD) has a market capitalization of $821.73M with a current stock price of $14.32.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In